Skip to main content
. 2018 Dec;10(12):6677–6694. doi: 10.21037/jtd.2018.11.87

Figure 5.

Figure 5

Pairwise comparisons: median PFS HR and median of median PFS. carbo, carboplatin; cis, cisplatin; doc, docetaxel; erlot, erlotinib; gem, gemcitabine; HR, hazard ratio; nab-tax, nab-paclitaxel; neci, necitumumab; PFS, progression-free survival; tax, paclitaxel; vin, vinorelbine.